Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib
Daraxonrasib improved survival in metastatic pancreatic cancer in the Phase III RASolute 302 trial, showing activity across diverse RAS variants. As the field turns its attention to AACR, the results highlight meaningful progress against one of oncology’s most RAS‑driven diseases. The post Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.